Clinical Trial Detail

NCT ID NCT03634332
Title Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pancreatic Cancer Research Team
Indications

pancreatic ductal adenocarcinoma

Therapies

PEGPH20 + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.